UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Stable Hyperbolic Limit Cycles for a Class of Differential Systems

Russian mathematics, 2021-09, Vol.65 (9), p.41-51

2021

Volltextzugriff (PDF)

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2017-09, Vol.18 (9), p.1274-1284

2017

Volltextzugriff (PDF)

A class of planar differential systems with explicit expression for two limit cycles

Siberian electronic mathematical reports, 2020-10, Vol.17, p.1588-1597

2020

Volltextzugriff (PDF)

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2021-05, Vol.22 (5), p.620-631

2021

Volltextzugriff (PDF)

793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)

Annals of oncology, 2023-10, Vol.34, p.S532-S532

2023

Volltextzugriff (PDF)

Potential nosocomial disseminated infection due to Nocardia asteroides after a prosthesis insertion in an immunocompetent patient

La revue de medecine interne, 2008-12, Vol.29 (12), p.1034-1037

2008

Volltextzugriff (PDF)

Nocardiose disséminée nosocomiale probable après chirurgie prothétique ostéoarticulaire chez un patient immunocompétent

La revue de medecine interne, 2008-12, Vol.29 (12), p.1034-1037

2008

Volltextzugriff (PDF)

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

European journal of cancer (1990), 2017-09, Vol.82, p.237-246

2017

Volltextzugriff (PDF)

Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Annals of oncology, 2019-10, Vol.30, p.v415

2019

Volltextzugriff (PDF)

Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Annals of oncology, 2019-10, Vol.30, p.v783-v784

2019

Volltextzugriff (PDF)

1036P - Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

Annals of oncology, 2019-10, Vol.30, p.v423-v423

2019

Volltextzugriff (PDF)

1036PTumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1016PSurrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1945PComparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

Annals of oncology, 2019-10, Vol.30, p.v423

2019

Volltextzugriff (PDF)

1945P - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Annals of oncology, 2019-10, Vol.30, p.v783-v784

2019

Volltextzugriff (PDF)

1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Annals of oncology, 2019-10, Vol.30, p.v415-v415

2019

Volltextzugriff (PDF)

Valeur pronostique de la cinétique précoce de l’ADN tumoral circulant en cours de chimiothérapie néoadjuvante pour les patientes présentant un cancer épithélial de l’ovaire à un stade avancé. Résultats préliminaires d’une analyse ancillaire de l’étude de phase II CHIVA (ARCAGY-GINECO)

Gynécologie, obstétrique, fertilité & sénologie, 2024-05, Vol.52 (5), p.348-349

2024

Volltextzugriff (PDF)

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

OncoTargets and therapy, 2013-01, Vol.6, p.89-94

2013

Volltextzugriff (PDF)

939TiPRANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE II TRIAL OF NINTEDANIB VERSUS PLACEBO IN ADVANCED OVARIAN CANCER (OC) PATIENTS TREATED WITH NEO-ADJUVANT CHEMOTHERAPY (NACX) AND INTERVAL DEBULKING SURGERY (IDS):THE CHIVA TRIAL FROM GINECO

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv324-iv324

2014

Volltextzugriff (PDF)

Randomized Double Blind Placebo-Controlled Phase Ii Trial of Nintedanib Versus Placebo in Advanced Ovarian Cancer (Oc) Patients Treated with Neo-Adjuvant Chemotherapy (Nacx) and Interval Debulking Surgery (Ids):The Chiva Trial from Gineco

Annals of oncology, 2014-09, Vol.25, p.iv324

2014

Volltextzugriff (PDF)

La chimiothérapie métronomique du cancer du sein métastatique: à propos d’un cas

Oncologie (Paris, France), 2010-07, Vol.12 (7), p.436-439

2010

Volltextzugriff (PDF)

La chimiothérapie métronomique du cancer du sein métastatique: à propos d'un cas: Biologie des cancers

Oncologie (Paris, France), 2010, Vol.12 (7), p.436-439

2010

Volltextzugriff (PDF)

Etoposide-based therapy for severe forms of COVID-19

Medical hypotheses, 2020-09, Vol.142, p.109826-109826, Article 109826

2020

Volltextzugriff (PDF)

Revised Jiang model's 'New formula of prediction of lattice constant in cubic perovskites'

Acta crystallographica. Section A, Foundations and advances, 2018-08, Vol.74 (a2), p.e269-e269

2018

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Technology
(29)
Physical Sciences
(28)
Engineering
(21)
Life Sciences & Biomedicine
(14)
Chemistry
(13)
Materials Science
(13)
Chemical Synthesis
(11)
Materials Science, Multidisciplinary
(10)
Physics
(10)
Science & Technology - Other Topics
(10)
Humans
(9)
Spectrum Analysis
(9)
Catalysts
(8)
Oncology
(8)
Electrochemistry
(7)
Middle Aged
(7)
Optical Properties
(7)
Acids
(6)
Female
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Stable Hyperbolic Limit Cycles for a Class of Differential Systems

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

A class of planar differential systems with explicit expression for two limit cycles

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)

Potential nosocomial disseminated infection due to Nocardia asteroides after a prosthesis insertion in an immunocompetent patient

Nocardiose disséminée nosocomiale probable après chirurgie prothétique ostéoarticulaire chez un patient immunocompétent

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

1036P - Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

1036PTumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

1016PSurrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

1945PComparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

Tumour microvessel density for predicting nintedanib activity: Data from the randomized CHIVA trial (a GINECO study)

1945P - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study)

1016P - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

939TiPRANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE II TRIAL OF NINTEDANIB VERSUS PLACEBO IN ADVANCED OVARIAN CANCER (OC) PATIENTS TREATED WITH NEO-ADJUVANT CHEMOTHERAPY (NACX) AND INTERVAL DEBULKING SURGERY (IDS):THE CHIVA TRIAL FROM GINECO

Randomized Double Blind Placebo-Controlled Phase Ii Trial of Nintedanib Versus Placebo in Advanced Ovarian Cancer (Oc) Patients Treated with Neo-Adjuvant Chemotherapy (Nacx) and Interval Debulking Surgery (Ids):The Chiva Trial from Gineco

La chimiothérapie métronomique du cancer du sein métastatique: à propos d’un cas

La chimiothérapie métronomique du cancer du sein métastatique: à propos d'un cas: Biologie des cancers

Etoposide-based therapy for severe forms of COVID-19

Revised Jiang model's 'New formula of prediction of lattice constant in cubic perovskites'

Suchergebnisse filtern